[1] Smith TJ, Hegedüs L. Graves' Disease. N Engl J Med. 2016; 375(16):1552– 1565.
[2] 医療情報科学研究所 編. 病気が見える vol.3： 糖尿病・代謝・内分泌. MEDIC MEDIA; 2008
[3] 西川光重, 成瀬光栄, 田上哲也, 伊藤公一 編. 甲状腺疾患診療マニュアル 改訂 第 3 版. 診断と治療社; 2020
[4] 日本甲状腺学会. 甲状腺疾患診断ガイドライン 2013. http://www.japanthyroid.jp/doctor/guideline/japanese.html#basedou. (アクセ ス日 2020/10/20)
[5] Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab. 2012; 97(12): 4549–4558.
[6] Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, Goldsmith SJ, Jadvar H, Marcus CS, Martin WH, Parker JA, Royal HD, Sarkar SD, Stabin M, Waxman AD. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012; 53(10): 1633–1651.
[7] Marinelli LD, Quimby EH, Hine GJ. Dosage determination with radioactive isotopes; practical considerations in therapy and protection. Am J Roentgenol Radium Ther. 1948; 59(2): 260–281.
[8] 日本甲状腺学会「バセドウ病 131I 内用療法の手引き」作成委員会：バセドウ病 131I 内用療法の手引き．日本甲状腺学会, 京都, 2007
[9] 日本核医学会分科会, 腫瘍・免疫核医学研究会,甲状腺 RI 治療委員会 編. 甲状 腺癌の放射性ヨウ素内用療法に関するガイドライン 第 6 版. http://oncology.jsnm.org/files/pdf/thyroid-guideline_06_2018.pdf（アクセス日 2020/10/20）
[10] Stokkel MP, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010; 37(11): 2218–2228
[11] Hänscheid H, Canzi C, Eschner W, Flux G, Luster M, Strigari L, Lassmann M. EANM Dosimetry Committee series on standard operational procedures for pretherapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. Eur J Nucl Med Mol Imaging. 2013; 40(7): 1126–1134
[12] Hermans R, Bouillon R, Laga K, Delaere PR, Foer BD, Marchal G, Baert AL. Estimation of thyroid gland volume by spiral computed tomography. Eur Radiol. 1997; 7(2): 214–216.
[13] Shu J, Zhao J, Guo D, Luo Y, Zhong W, Xie W. Accuracy and reliability of thyroid volumetry using spiral CT and thyroid volume in a healthy, non-iodinedeficient Chinese adult population. Eur J Radiol. 2011; 77(2): 274–280.
[14] Lee SJ, Chong S, Kang KH, Hur J, Hong BW, Kim HJ, Kim SJ. Semiautomated thyroid volumetry using 3D CT: prospective comparison with measurements obtained using 2D ultrasound, 2D CT, and water displacement method of specimen. AJR Am J Roentgenol. 2014; 203(5): W525–532.
[15] Veres C, Garsi JP, Rubino C, Pouzoulet F, Bidault F, Chavaudra J, Bridier A, Ricard M, Ferreira I, Lefkopoulos D, de Vathaire F, Diallo I. Thyroid volume measurement in external beam radiotherapy patients using CT imaging: correlation with clinical and anthropometric characteristics. Phys Med Biol. 2010; 55(21): N507–519.
[16] Nygaard B, Nygaard T, Court-Payen M, Jensen LI, Søe-Jensen P, Gerhard Nielsen K, Fugl M, Hegedüs L. Thyroid volume measured by ultrasonography and CT. Acta Radiol. 2002; 43(3): 269–274.
[17] van Isselt JW, de Klerk JM, van Rijk PP, van Gils AP, Polman LJ, Kamphuis C, Meijer R, Beekman FJ. Comparison of methods for thyroid volume estimation in patients with Graves' disease. Eur J Nucl Med Mol Imaging. 2003; 30(4): 525– 531.
[18] Snyder WS, Ford MR, Warner GG, Watson SB. MIRD pamphlet No. 11: S, absorbed dose per unit cumulated activity for selected radionuclides and organs. New York; Society of Nuclear Medicine; 1975
[19] Berman M. MIRD pamphlet No. 12: kinetic models for absorbed dose calculations. New York; Society of Nuclear Medicine; 1977
[20] Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, Robertson JS, Howell RW, Wessels BW, Fisher DR, Weber DA, Brill AB. MIRD pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999; 40(2): 37S–61S.
[21] Bolch WE, Bouchet LG, Robertson JS, Wessels BW, Siegel JA, Howell RW, Erdi AK, Aydogan B, Costes S, Watson EE, Brill AB, Charkes ND, Fisher DR, Hays MT, Thomas SR. MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions—radionuclide S values at the voxel level. J Nucl Med. 1999; 40(1): 11S–36S.
[22] Goodwin WE, Cassen B, Bauer FK. Thyroid gland weight determination from thyroid scintigrams with postmortem verification. Radiology. 1953; 61(1): 88– 92.
[23] Allen HC Jr, Goodwin WE. The scintillation counter as an instrument for in vivo determination of thyroid weight. Radiology. 1952; 58(1): 68–79.
[24] Malago R, D'Onofrio M, Ferdeghini M, Mantovani W, Colato C, Brazzarola P, Motton M, Mucelli RP. Thyroid volumetric quantification: comparative evaluation between conventional and volumetric ultrasonography. J Ultrasound Med. 2008; 27(12): 1727–1733.
[25] Schlögl S, Werner E, Lassmann M, Terekhova J, Muffert S, Seybold S, Reiners C. The use of three-dimensional ultrasound for thyroid volumetry. Thyroid. 2001; 11(6): 569–574
[26] Heywood H. Numerical definitions of particle size and shape. Chem. Ind. 1937; 56(7): 149–154
[27] Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989; 45(1): 255–268.
[28] McBride GB. A proposal for strength-of-agreement criteria for Lins Concordance Correlation Coefficient. NIWA Client Report 2005: HAM2005– 062.
[29] Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest. 1995; 25(3): 186–193.
[30] Huysmans DA, de Haas MM, van den Broek WJ, Hermus AR, Barentsz JO, Corstens FH, Ruijs SH. Magnetic resonance imaging for volume estimation of large multinodular goitres: a comparison with scintigraphy. Br J Radiol. 1994; 67(798): 519–523.
[31] Chapman EM. History of the discovery and early use of radioactive iodine. JAMA. 1983; 250(15): 2042–2044.
[32] Hertz S, Roberts A, Salter WT. Radioactive iodine as an indicator in thyroid physiology. IV. The metabolism of iodine in Graves' disease. J Clin Invest. 1942; 21(1): 25–29.
[33] Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, Krause TM. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging. 2002; 29(9): 1118–1124.
[34] Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G, Volterrani D, Chiacchio S, AlSharif A, Borsò E, Raschillà R, Di Martino F, Mariani G. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism. Cancer Biother Radiopharm. 2005; 20(2): 218–223.
[35] Carlier T, Salaun PY, Cavarec MB, Valette F, Turzo A, Bardiès M, Bizais Y, Couturier O. Optimized radioiodine therapy for Graves' disease: two MIRDbased models for the computation of patient-specific therapeutic 131I activity. Nucl Med Commun. 2006; 27(7): 559–566.
[36] Di Martino F, Traino AC, Brill AB, Stabin MG, Lazzer M. A theoretical model for prescription of the patient-specific therapeutic activity for radioiodine therapy of Graves' disease. Phys Med Biol. 2002; 47(9): 1493–1499.
[37] Dewaraja YK, Ljungberg M, Green AJ, Zanzonico PB, Frey EC, Bolch WE, Brill AB, Dunphy M, Fisher DR, Howell RW, Meredith RF, Sgouros G, Wessels BW. MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications. J Nucl Med. 2013; 54(12): 2182–2188.
[38] Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K, Bolch WE, Brill AB, Fahey F, Fisher DR, Hobbs R, Howell RW, Meredith RF, Sgouros G, Zanzonico P, Bacher K, Chiesa C, Flux G, Lassmann M, Strigari L, Walrand S. MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. J Nucl Med. 2016; 57(1): 151–162.
[39] Hänscheid H, Lassmann M, Reiners C. Dosimetry prior to I-131-therapy of benign thyroid disease. Z Med Phys. 2011; 21(4): 250–257.
[40] Zeintl J, Vija AH, Yahil A, Hornegger J, Kuwert T. Quantitative accuracy of clinical 99mTc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction. J Nucl Med. 2010; 51(6): 921–928.
[41] Matsutomo N, Matsumoto S, Yamamoto T, Sato E. Validation of a calibration method using the cross-calibration factor and system planar sensitivity in quantitative single-photon emission computed tomography imaging. Radiol Phys Technol. 2017; 10(4): 439–445.
[42] Bockisch A, Jamitzky T, Derwanz R, Biersack HJ. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med. 1993; 34(10): 1632163–8.
[43] Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998; 39(5): 904–911.
[44] Japanese engineering standards of radiological apparatus. JESRA X-0051*C2017 test condition and its expressions of gamma camera performances. Tokyo: Japanese engineering standards of radiological apparatus; 2017
[45] Thomas BA, Cuplov V, Bousse A, Mendes A, Thielemans K, Hutton BF, Erlandsson K. PETPVC: a toolbox for performing partial volume correction techniques in positron emission tomography. Phys Med Biol. 2016; 61(22): 7975–7993.
[46] Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001; 86(8): 3611–3617.
[47] Seed L, Jaffe B. Comparison of the tracer dose and the therapeutic dose of I131 as to thyroid uptake, effective half-life, and roentgen dosage. Radiology. 1954; 63(4): 551–561.
[48] Canzi C, Zito F, Voltini F, Reschini E, Gerundini P. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients. Med Phys. 2006; 33(8): 2860–2867.
[49] Gregory RA, Murray I, Gear J, Leek F, Chittenden S, Fenwick A, Wevrett J, Scuffham J, Tipping J, Murby B, Jeans S, Stuffins M, Michopoulou S, Guy M, Morgan D, Hallam A, Hall D, Polydor H, Brown C, Gillen G, Dickson N, Brown S, Wadsley J, Flux G. Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy. Phys Med Biol. 2019; 64(24): 245013.
論文の公開元へ
